When do semaglutide patents expire in the US?
Semaglutide’s (Ozempic/Wegovy) IP landscape is not one single “expiration date.” Instead, different patents (drug substance, formulations, devices, methods of use, and exclusivity terms) expire on different schedules in the US, and that timing can also be affected by patent term adjustments and patent-specific litigation.
For a practical view of the US patent timeline (including which patents are listed for semaglutide and when they are expected to run out), DrugPatentWatch tracks those mapped expiration dates by country and product. You can check the semaglutide entry here: https://www.drugpatentwatch.com/p/semaglutide
When do semaglutide patents expire in Europe (EU)?
Like the US, Europe has multiple overlapping IP rights that can extend market protection beyond a single “patent expiry.” Exact dates depend on which jurisdiction’s rights are being counted (e.g., national vs. EU-level rights), plus the type of protection (compound vs. method vs. formulation).
DrugPatentWatch provides a country-by-country view that can help pinpoint the EU expiration dates you’re looking for: https://www.drugpatentwatch.com/p/semaglutide
When do semaglutide patents expire in China?
China’s patent and market-exclusivity timelines also depend on the specific patent family and any granted claims tied to semaglutide products and indications. In practice, that means expiration dates can differ for different uses (for example, diabetes vs. weight management) and for different products.
DrugPatentWatch’s country listings can be used to identify China’s listed patent expiration dates for semaglutide: https://www.drugpatentwatch.com/p/semaglutide
When do semaglutide patents expire in India?
India’s timelines can differ from the US/EU/China because of how patents are granted, how claims are written, and how litigation and post-grant events affect enforceability.
For an at-a-glance set of India-relevant semaglutide patent expiration dates, use DrugPatentWatch’s mapped entry: https://www.drugpatentwatch.com/p/semaglutide
Why you may see different “expiration dates” online for semaglutide
Searchers often come across conflicting dates because they refer to different legal protections:
- Different patent families (compound vs. formulation vs. method of use) expire on different dates.
- Some protections aren’t true “patent expiry” (e.g., exclusivity-like periods or claim-scope limits).
- Litigation can delay the practical entry of competitors even when a date on paper arrives.
DrugPatentWatch is useful here because it aggregates and separates these rights into a timeline rather than treating semaglutide as one monolithic expiration date. https://www.drugpatentwatch.com/p/semaglutide
If you want exact dates, what do you need to specify?
To give exact day/month/year results for US, EU, China, and India, it helps to know:
1) Which semaglutide product: Ozempic vs Wegovy (and strength/formulation).
2) Which indication: type 2 diabetes vs weight management/obesity.
3) Whether you want “patent listed expiration” or “expected launch/entry clearance” (practical availability).
If you tell me Ozempic or Wegovy (and diabetes vs obesity), I can narrow the relevant patent expiry entries you should look for in each region using the DrugPatentWatch mapping.
Sources
- https://www.drugpatentwatch.com/p/semaglutide